Vertex Pharma's Sales Fall Short Due to Lackluster Demand for Established CF Therapies
Vertex Pharmaceuticals missed sales estimates for its older cystic fibrosis (CF) treatments in the third quarter, with a 35.4% decline in sales. The company now expects annual sales of approximately $9.85 billion from its CF treatments. However, sales of its top-selling CF drug, Trikafta, came in at $2.27 billion, slightly exceeding estimates. Vertex anticipates continued growth in the number of CF patients taking its medicines, including through new approvals and reimbursement for treatment of younger patients.